THE KIDNEY AND CARDIOVASCULAR RISK

June 10 - 09.00-18.30 hrs.

Workshop on Renin-angiotensin system, dyslipidemia and chronic renal failure
Chairpersons:
G. Cerasola (Palermo, Italy)
S. Novo (Palermo, Italy)

Epidemiology and pathophysiology of chronic renal failure
V.E. Andreucci (Naples, Italy)

Renin-angiotensin system, cardiovascular and renal risk
B. Trimarco (Naples, Italy)

Dyslipidemia and chronic renal failure: role of statins
S. Bianchi (Livorno, Italy)

Discussion

Welcome coffee and opening remarks

Main lecture
Chairperson: F.P. Schena (Bari, Italy)

Nephron number and renal risk in hypertension and diabetes
E. Ritz (Heidelberg, Germany)

SESSION I
The kidney and arterial hypertension
Chairpersons:
A. Pessina (Padua, Italy)
A. Rappelli (Ancona, Italy)

Cardiovascular comorbidity in chronic kidney disease in Europe
F. Locatelli (Lecco, Italy)
The kidney as villain and victim of hypertension
G.A. Cinotti (Rome, Italy)

Calcium channel blockers, the kidney and hypertension: insights from latest clinical trials
L.M. Ruilope (Madrid, Spain)

Discussion

Main Lecture
Chairperson: A. Santucci (L’Aquila, Italy)

Multifactorial aspects of cardiovascular risk
G. Mancia (Milan, Italy)

Discussion

Lunch

SESSION II

The kidney and malnutrition
Chairpersons:
E. Ambrosioni (Bologna, Italy)
C. Zoccali (Reggio Calabria, Italy)

Predictor of renal dysfunction in a large Italian cohort (The Olivetti Prospective Heart Study)
P. Strazzullo (Naples, Italy)

Malnutrition and cardiovascular risk in chronic kidney disease
S. Cottone (Palermo, Italy)

Calcium-phosphorus metabolism, PTH and cardiovascular calcification in uremia
D. Brancaccio (Milan, Italy)

Anemia, erythropoietin and heart failure in chronic kidney disease
D. Silverberg (Tel Aviv, Israel)

Endotelium and ADMA at the crossroad of cardio-renal risk
C. Zoccali (Reggio Calabria, Italy)

Discussion

Coffee break

Main Lecture
Chairperson: V. Campese (Los Angeles, CA, USA)

Diabetic nephropathy: what we learned from it?
G.C. Viberti (London, UK)
SESSION III

The kidney and the heart

Chairpersons:
V.E. Andreucci (Naples, Italy)
G. Bellinghieri (Messina, Italy)
S. Novo (Palermo, Italy)

Left ventricular geometry and cardiovascular events in renal failure
G. De Simone (Naples, Italy)

Management of the patient with heart failure and renal insufficiency
M. Volpe (Rome, Italy)

Ultrafiltration in heart failure
G. Marenzi (Milan, Italy)

Cardiovascular events in dialysis patient: best cardiac protection
F.P. Schena (Bari, Italy)

Sudden death in the uremic patient
G. Cannella (Genoa, Italy)

Discussion

Coffee break

SESSION IV

Cardiac and renal protection

Chairpersons:
G. Leonetti (Milan, Italy)
G. Licata (Palermo, Italy)

Microalbuminuria, an integrated marker of cardiovascular damage in arterial hypertension
G. Cerasola (Palermo, Italy)

Cardiac protection in hypertensive diabetic patient: Prime project, RENAAL and Life studies
E. Agabiti Rosei (Brescia, Italy)

Progression of kidney disease: is ACE-Inhibition or AT-1 receptor blockade the solution to the problem?
V. Campese (Los Angeles, CA, USA)

Lipids, atherosclerosis and chronic kidney disease
A. Notarbartolo (Palermo, Italy)

Discussion

Closing Remarks
PREVENTION OF ARTERIAL HYPERTENSION

Is prevention of arterial hypertension possible?
Chairpersons:
A. Januszewicz (Warsaw, Poland)
K. Kawecka-Jaszcz (Cracow, Poland)

Development of hypertension care in Finland
A. Nissinen (Helsinki, Finland)

The dynamics of alcohol and blood pressure
A. Evans (Belfast, UK)

Nonpharmacological aspects and arterial hypertension in Kraków
A. Pająk (Cracow, Poland)

Can we improve the efficacy of antihypertensive treatment?
Chairpersons:
Z. Gaciong (Warsaw, Poland)
P. Podolec (Cracow, Poland)

Choice of antihypertensive agents and therapeutic efficacy
K. Narkiewicz (Gdańsk, Poland)

The patient with high normal blood pressure - to treat or not to treat?
D. Czarnecka (Cracow, Poland)

Refractory arterial hypertension
A. Tykarski (Poznan, Poland)

Education of hypertensive patients
T. Grodzicki (Cracow, Poland)

How to improve therapeutic efficacy in the elderly?
B. Gryglewska (Cracow, Poland)
Arterial hypertension as a public health issue - panel discussion
Chairpersons:
R. Cífková (Prague, Czech Republic)
A. Rynkiewicz (Gdansk, Poland)

Panel:
A. Nissinen (Helsinki, Finland)
R. Cífková (Prague, Czech Republic)
P. Jonas (Kosice, Slovakia)
G. Sakalnikas (Kaunas, Lithuania)
V. Dzerve (Riga, Latvia)
R. Accetto (Ljubljana, Slovenia)
T. Zdrojewski (Gdansk, Poland)
NEW INSIGHTS IN FACTORS PROMOTING RENAL DAMAGE

Registration and lunch

Tissue factors
Chairpersons:
G. D’Amico (Milan, Italy)
A. Dal Canton (Pavia, Italy)

Cytokines in the progression of renal damage
H. Haller (Hannover, Germany)

Renin-Angiotensin-System and extracellular matrix turnover
A. Stella (Monza-MI, Italy)

Epithelial-mesenchimal transition promotes renal fibrosis
M.P. Rastaldi (Milan, Italy)

Discussion

Systemic factors
Chairpersons:
G. Buccianti (Monza-MI, Italy)
D. Cusi (Milan, Italy)

ESRD: role of arterial hypertension
L.M. Ruilope (Madrid, Spain)

ESRD: role of metabolic syndrome
T.F. Lüscher (Zurich, Switzerland)

Anemia: an emerging renal and cardiovascular risk
C. Zoccali (Reggio Calabria, Italy)

Discussion

Coffee break
Therapeutic aspects
Chairpersons:
G. Cinotti (Rome, Italy)
A. Morganti (Milan, Italy)

Role of HMG-CoA reductase inhibitors in the prevention of ESRD
E. Ritz (Heidelberg, Germany)

Drug association in blocking the progression of renal disease
R. Pontremoli (Genoa, Italy)

Regression of renal and cardiovascular disease: future perspectives
P. Ruggenenti (Bergamo, Italy)

It’s time for pharmacogenomics?
G. Bianchi (Milan, Italy)

Discussion

Closing remarks
G. Mancia (Monza, Italy)

CME questionnaire
A. Stella (Monza-MI, Italy)
CARdiorespiratory Effects of HyPOXIA: FROM HIGH ALTITUDE TO BEDSIDE

International Workshop endorsed by the ESH Working Group on Blood Pressure and Heart Rate Variability

Endorsed by COST Action B26 - Obstructive Sleep Apnea European Cooperation in the Field of Scientific and Technical Research

COST is supported by the EU Framework Programme

Welcome
G. Ancarani (Milan, Italy)
A. Zanchetti (Milan, Italy)

Adaptation to high altitude hypoxia
Chairpersons:
G. Miserocchi (Milan, Italy)
J. Pouysségur (Nice, France)

HIF gene expression and hypoxia signaling
J. Pouysségur (Nice, France)

A role for endothelin in the response to hypoxia at altitude
P. Modesti (Florence, Italy)

Periodic breathing at altitude
G. Insalaco (Palermo, Italy)

Extravascular lung fluid accumulation at high altitude in recreational and elite climbers
A. Cogo (Ferrara, Italy)

Hypoxic interstitial pulmonary edema
G. Miserocchi (Milan, Italy)

Coffee break
Effects of hypoxia on physiologic control mechanisms
Chairpersons:
K. Narkiewicz (Gdansk, Poland)
G. Parati (Milan, Italy)

Chemoreflex activation at altitude and in congestive heart failure patients
P. van De Borne (Brussels, Belgium)

Muscle sympathetic nerve activity under hypoxic conditions and in CHF patients
K. Narkiewicz (Gdansk, Poland)

Baroreflex function and cardiovascular variability at altitude and in CHF patients
G. Bilo (Milan, Italy and Cracow, Poland)

Autonomic and humoral cardiovascular regulation in hypoxic obese subjects
A. Pathak (Toulouse, France)

Metabolic effects of hypoxia at altitude and in obesity
G. Savia (Milan and Verbania, Italy)

CRP, leptin, neuropeptide Y in obese patients and in OSAS
F. Barbé (Palma De Mallorca, Spain)

Lunch

Counteracting the effects of hypoxia at altitude and in chronic hypoxic patients
Chairpersons:
G. Mancia (Milan, Italy)
K. Narkiewicz (Gdansk, Poland)

DLCO and exercise performance in heart failure: a role only in hypoxic conditions or also with normoxic air breathing?
P. Agostoni (Milan, Italy)

Intermittent exposure to controlled hypoxia: a role for interval hypoxic training in improving response to hypoxia?
I. Ehrenbourg (Moscow, Russia)

Slow breathing exercise and adaptation to hypoxia at altitude and in CHF patients
G. Parati (Milan, Italy)

CPAP treatment, sleep disordered breathing and hypoxia in patients with cardiorespiratory disease
A. Braghiroli (Veruno-NO, Italy)

Conclusions
G. Mancia (Milan, Italy), G. Parati (Milan, Italy)
Welcome and introduction

Do patient age, sex and baseline blood pressure matter?
The evidence for selecting particular agents for certain patient groups
B. Neal (Sydney, Australia)

Blood pressure lowering in diabetes: results from the Trialists’ overviews and ALLHAT
B. Davis (Houston, TX, USA)

Afternoon tea

New evidence of blood pressure-independent effects for agents acting via the renin-angiotensin system
F. Turnbull (Sidney, Australia)

Making the blood pressure messages clear: implications for blood pressure guidelines
G. Mancia (Milan, Italy)

Discussion
VASCULAR DAMAGE IN HYPERTENSION. ASSESSMENT, PATHOPHYSIOLOGY, TREATMENT

Microcirculation
Chairpersons:
E. Agabiti Rosei (Brescia, Italy)
M. Volpe (Rome, Italy)

Speakers and Discussants:
A.M. Heagerty (Manchester, UK)
A. Salvetti (Pisa, Italy)
L.M. Ruilope (Madrid, Spain)

Coffee break

Large arteries stiffness
Chairpersons:
G. Leonetti (Milan, Italy)
B. Trimarco (Naples, Italy)

Speakers and Discussants:
J. Redon (Madrid, Spain)
S. Laurent (Paris, France)
M. Safar (Paris, France)
G. Mancia (Milan, Italy)

Lunch

Atherosclerotic plaque
Chairpersons:
M. Alderman (New York, NY, USA)
E. Ambrosioni (Bologna, Italy)
Speakers and Discussants:
H. Haller (Hannover, Germany)
A. Zanchetti (Milan, Italy)
A. Pessina (Padua, Italy)
A. Manolis (Athens, Greece)
A. Rappelli (Ancona, Italy)

Summary and closing
G. Mancia (Milan, Italy)
E. Agabiti Rosei (Brescia, Italy)
HEART RATE, SYMPATHETIC OVERACTIVITY AND THE CARDIOVASCULAR RISK

I SESSION
Chairpersons:
G. Mancia (Milan, Italy)
S. Julius (Ann Arbor, MI, USA)

Heart rate as a marker of autonomic imbalance
G. Parati (Milan, Italy)

Interactive effect of heart rate and sympathetic activity on blood pressure
K. Narkiewicz (Gdansk, Poland)

Discussion
G. Parati (Milan, Italy)
K. Narkiewicz (Gdansk, Poland)

II SESSION
Chairpersons:
C. Dal Palù (Padua, Italy)
A. Zanchetti (Milan, Italy)

Sympathetic overactivity in the obese: role of fat distribution
G. Grassi (Milan, Italy)

Connection between sympathetic overactivity and overweight in hypertension
M.C. Valentini (Milan, Italy)

Discussion
G. Grassi (Milan, Italy)
M.C. Valentini (Milan, Italy)

Coffee break
III SESSION
Chairpersons:
A.C. Pessina (Padua, Italy)
K. Narkiewicz (Gdansk, Poland)

Tachycardia and the metabolic syndrome
P. Strazzullo (Naples, Italy)

Links between heart rate and blood pressure
M. Winnicki (Padua, Italy)

Evidence for heart rate as a cardiovascular risk factor
P. Palatini (Padua, Italy)

Discussion
P. Strazzullo (Naples, Italy)
M. Winnicki (Padua, Italy)
P. Palatini (Padua, Italy)

Lunch

IV SESSION
Chairpersons:
S. Julius (Ann Arbor, MI, USA)
A. Zanchetti (Milan, Italy)

Roundtable discussion:
- Methods of measurement for resting heart rate
- Upper normal limits for heart rate as a risk factor
- Treatment of tachycardia in the normotensive and the hypertensive subject
  G. Mancia (Milan, Italy)
P. Palatini (Padua, Italy)
A.C. Pessina (Padua, Italy)

CME Questionnaire
P. Palatini (Padua, Italy)
**METABOLIC SYNDROME: A GROWING CHALLENGE**

**FRIDAY, JULY 15, 2005 - 18.15/21.00**

**President’s Welcome**

**LECTURE**
Results of recent clinical trials
H. Gavras (*Boston, MA, USA*)

**LECTURE**
Is it the time to update of the ESH guidelines
G. Mancia (*Milan, Italy*)

Welcome reception and dinner

**SATURDAY, JULY 16, 2005 - 08.00/19.00**

**Breakfast Research Meeting**

**LECTURE**
Prevalence and definition of the MetS
W. Alexander (*Atlanta, GA, USA*)

**1st SESSION**
Pathophysiology and mechanisms of the MetS

**Insulin resistance**
T. Alexandridis (*Patras, Greece*)

**Obesity**
G. Panotopoulos (*Athens, Greece*)

**Hyperlipidemia**
M. Elisaf (*Ioannina, Greece*)

**Hypertension**
S. Erdine (*Istanbul, Turkey*)
Sympathetic nervous system and the MetS
G. Grassi (Milan, Italy)

Coffee break

2nd SESSION
MetS and target organ damage

Kidneys
G. Bakris (Chicago, IL, USA)

Heart and vessels
E. Agabiti Rosei (Brescia, Italy)

New onset of diabetes
H. Brunner (Lausanne, Switzerland)

Sexual dysfunction
D. Chatzichristos (Thessaloniki, Greece)

LECTURE
Endocannabinoid system: a novel therapeutic target for the management of multiple CV risk factors
D. Michailides (UK)

3rd SESSION
Are we ready to treat the MetS?

Obesity
K. Narkiewicz (Gdansk, Poland)

Diabetes mellitus
A. Mitrakou (Athens, Greece)

Hyperlipidemia
G. Kolovou (Athens, Greece)

Hypertension
C. Zamboulis (Thessaloniki, Greece)

Combination treatment: What's new?
C. Farsang (Budapest, Hungary)

Overview of the MetS.
Do we need new, and more accurate criteria?
A. Heagerty (Manchester, UK)